Back

CD137-targeted therapy market report tracks more than 90 clinical programs through 2030

Verifying
  • ResearchAndMarkets.com added a report covering the global CD137-targeted therapy market and clinical pipeline.
  • More than 90 CD137-targeted therapies are in clinical development, with programs reaching Phase III.
  • The first commercial launch of a CD137-targeted therapy is expected by 2030.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.